SOUTH SAN FRANCISCO, Calif., May 01, 2024–(BUSINESS WIRE)–Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will participate in two upcoming investor conferences taking place in May. The JMP
Kiniksa Pharmaceuticals, Ltd. – ARCALYST® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $370 – $390 million –– Abiprubart Phase 2b trial in Sjögren’s Disease planned to initiate in 2H 2024 –– Current operating plan expected to remain cash flow positive
Arbutus Biopharma Corporation WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it has scheduled its first quarter 2024 financial results and corporate update for
Clinuvel Pharmaceuticals Limited DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) — Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide) and the future of photomedicine. Over 70 guests discussed the Company’s unique history and future growth potential at an invitation-only event in Düsseldorf. Managing Director and CEO, Dr
Revenue: Dropped to $0.8 million in 2023 from $44.7 million in 2022, primarily due to decreased Vaxzevria sales. Net Loss: Expanded to $73.3 million, or $1.91 per share, reversing the prior year’s net income of $5.3 million, or $0.14 per share. Cash Position: Decreased to $142.1 million at year-end 2023 from $194.4 million at the